Clinical trials: Malignant Melanomas
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Melanoma
Imatinib in Adult Patients With Metastatic Ocular Melanoma
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
- Trial name
- O-Mel-Inib (NCT00421317)
- Testing
- Imatinib
- Where
- 12 sites in France
- Volunteers
- 13 people
- Sponsor
- Centre Oscar Lambret
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Colorectal Cancer Metastatic, Metastatic Melanoma
The Jules Bordet Institute Molecular Profiling Program Feasibility Trial
Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by examining the feasibility and turnaround time of…
- Conditions
- Colorectal Cancer Metastatic, Metastatic Melanoma, Metastatic Non-Small Cell Lung Carcinoma
- Trial name
- PRECISION-F (NCT01932489)
- Testing
- Biopsy of a metastatic lesion.
- Where
- Belgium
- Volunteers
- 35 people
- Sponsor
- Jules Bordet Institute
Uveal Melanoma
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma.
- Trial name
- NCT07501117
- Testing
- Nivolumab & Ipilimumab
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Inge Marie Svane
Ocular Melanoma
The Role of Inflammation in Ocular Tumours
This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours. The investigators will evaluate 5 groups: 1.
- Trial name
- NCT02909517
- Testing
- cSLO imaging
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- Mel48 (NCT00705640)
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma (Skin)
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight infections and cancer. These CTL can be manipulated in the laboratory so that they can target an individual's cancer.
- Trial name
- NCT00512889
- Testing
- therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Circulating tumor cells (CTC) are the subject of increasing interest in clinical oncology as a prognostic factor and predictor of therapeutic response.
- Trial name
- NCT01573494
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Melanoma Stage Iv, Melanoma Stage Iii
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma.
- Conditions
- Melanoma Stage Iv, Melanoma Stage Iii, Melanoma
- Trial name
- CHARLI (NCT03161756)
- Testing
- Denosumab, Nivolumab, Ipilimumab
- Where
- 10 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.
- Trial name
- NCT05572463
- Testing
- Sintilimab + IBI110
- Where
- 13 sites in United States, Australia and 5 more
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Melanoma
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
This is an international multicenter, open-label, sequential phase study of intralesional (IL) PV-10 in combination with immune checkpoint inhibition.
- Trial name
- NCT02557321
- Testing
- PV-10, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Skin Cancer
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
This is a pilot study of a community- based melanoma educational intervention in Bensonhurst, Brooklyn conducted in-person by a community-health worker employed by the Perlmutter Cancer Center.
- Trial name
- NCT07177638
- Testing
- Education Sessions to Improve Melanoma Knowledge and Awareness
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Melanoma (Skin)
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00054535
- Testing
- aldesleukin, recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients
The effectiveness of propranolol in infantile hemangiomas, the apparent better response to propranolol in breast cancer and the use of propranolol in a proportion of patients who did not develop melanoma recurrence suggested to…
- Trial name
- NCT02962947
- Testing
- Propranolol
- Volunteers
- 546 people
- Sponsor
- Azienda Sanitaria di Firenze
Melanoma, Tumor Vaccines
Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma
The primary objective of this study is to evaluate the safety and tolerability of multiple sub-cutaneous injections of GeniusVac-Mel4, a dendritic cell-based cancer vaccine, in patients with melanoma.
- Conditions
- Melanoma, Tumor Vaccines, Effects of Immunotherapy
- Trial name
- GeniusVac-Mel4 (NCT01863108)
- Testing
- GeniusVac-Mel4
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Grenoble
GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
- Conditions
- GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
- Trial name
- NCT01328106
- Testing
- GSK1120212
- Sponsor
- GlaxoSmithKline
Renal Cell Carcinoma, Soft Tissue Sarcoma
HYPAZ: Hypertension Induced by Pazopanib
Pazopanib is a new cancer drug that works by limiting the growth of new blood vessels in tumours. About half of patients who take pazopanib develop high blood pressure (hypertension).
- Conditions
- Renal Cell Carcinoma, Soft Tissue Sarcoma, Glioblastoma, Ovarian Cancer
- Trial name
- HYPAZ (NCT01392352)
- Testing
- Pazopanib
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Skin Cancer
iToBoS Prospective Data Acquisition and Feasibility Study (Barcelona)
This study is recruiting patients at their regular skin examination appointments to participate in research. Participation involves having 3D total body photography, completing a 10-15 minute questionnaire, and providing a…
- Trial name
- iToBoS BCN (NCT05955443)
- Where
- Spain
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.